Skip to main content
Premium Trial:

Request an Annual Quote

OpGen: Yvonne Schlaeppi

OpGen has elected Yvonne Schlaeppi as a new, independent non-executive member of the company's board of directors. Since 2011, Schlaeppi has served as a managing partner of Stratevise, an international strategic advisory firm that she cofounded. From 2007 to 2011, she served as general counsel at Global Enterprise Technologies, Passport & ID, a high-security document printing solutions provider and systems integrator. Schlaeppia also previous served as executive VP, general counsel, and corporate IP officer at Organon BioSciences; and as a partner at the Boston-based law firm of Palmer & Dodge.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.